CSIMarket


Organogenesis Holdings Inc   (ORGO)
Other Ticker:  
 

Organogenesis Holdings Inc

ORGO's Fundamental analysis








Organogenesis Holdings Inc 's sales fell by -7.13 % in III. Quarter 2023 from the same quarter a year ago. Ranking at No. 2125

Major Pharmaceutical Preparations industry recorded deterioration of revenues by -4.74 %

Organogenesis Holdings Inc 's net income grew by 1373.02 % in III. Quarter 2023 year on year, above company average,

More on ORGO's Growth


Organogenesis Holdings Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Organogenesis Holdings Inc realized cash outflow of $ -0.07per share in trailing twelve-month period.
Company
32.17
PE TTM   
Industry
283.72
PE TTM    
Company's Price to Sales ratio is at 0.86.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.79.


More on ORGO's Valuation
 
 Total Debt (Millions $) 68
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 500,006
 Net Income/Employee (TTM) $ 13,393
 Receivable Turnover (TTM) 4.92
 Tangible Book Value (Per Share $) 1.73

Organogenesis Holdings Inc
current PE on trailing twelve month basis is below Major Pharmaceutical Preparations industry average.

Organogenesis Holdings Inc realized cash outflow of $ -0.07per share in trailing twelve-month period.
Company
32.17
PE TTM   
Industry
283.72
PE TTM    
Company's Price to Sales ratio is at 0.86.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.79.

Organogenesis Holdings Inc Price to Book Ratio is at 1.39 lower than Indusry Avg. of 1293.67. and higher than S&P 500 Avg. of -2037.67

More on ORGO's Valuation

  Market Capitalization (Millions $) 384
  Shares Outstanding (Millions) 133
  Employees 896
  Revenues (TTM) (Millions $) 448
  Net Income (TTM) (Millions $) 12
  Cash Flow (TTM) (Millions $) -9
  Capital Exp. (TTM) (Millions $) -32
  Total Debt (Millions $) 68
  Dividend TTM ($) 0 $
  Dividend Yield TTM (%) -
  Revenue/Employee (TTM) $ 500,006
  Net Income/Employee(TTM) $ 13,393
  Receivable Turnover Ratio (TTM) 4.92
  Tangible Book Value (Per Share $) 1.73

  Market Capitalization (Millions $) 384
  Shares Outstanding (Millions) 133
  Employees 896
  Revenues (TTM) (Millions $) 448
  Net Income (TTM) (Millions $) 12
  Cash Flow (TTM) (Millions $) -9
  Capital Exp. (TTM) (Millions $) -32


    ORGO's Profitability Comparisons
Organogenesis Holdings Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in III. Quarter 2023 to 7.42 % from 8.31 % in II. Quarter.

Organogenesis Holdings Inc net profit margin of 2.92 % is currently ranking no. 58 in Major Pharmaceutical Preparations industry, ranking no. 160 in Healthcare sector and number 2105 in S&P 500.





  Ratio
   Capital Ratio (MRQ) 2.77
  Total Debt to Equity (MRQ) 0.24
  Tangible Leverage Ratio (MRQ) 0.8
  Asset Turnover Ratio (TTM) 1.06
  Inventory Turnover Ratio (TTM) 4.09



Organogenesis Holdings Inc faced margin deterioraten, primarily through cost pressure. Operating Margin fell in III. Quarter 2023 to 7.42 % from 8.31 % in II. Quarter.

Organogenesis Holdings Inc net profit margin of 2.92 % is currently ranking no. 58 in Major Pharmaceutical Preparations industry, ranking no. 160 in Healthcare sector and number 2105 in S&P 500.

More on ORGO's Key Ratios





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com